IHE publishes today the fifth sub-report in a report series on cancer care and access to cancer drugs in Asia-Pacific.
This report describes the pricing policies for drugs after patentexpiry or loss of exclusivity seen across the region. It examines how effective they are in achieving low prices for cancer drugs. Around 5–20% of total cancer drug expenditure could be saved from more effective pricing policies.
Pricing policies for off-patent drugs in Asia-Pacific
IHE Report 2021:3g, IHE: Lund, Sweden